| Clinicopathological Features . | Functional ACC (n = 25) . | Nonfunctional ACC (n = 21) . | P . |
|---|---|---|---|
| Age at diagnosis, ya | 57.0 (44.0, 63.0) | 54.0 (42.5, 58.5) | 0.76 |
| Sex, male/female | 13/12 | 8/13 | 0.35 |
| Primary tumor size, cma | 9.23 (5.89, 10.95) | 7.90 (5.80, 10.21) | 0.70 |
| ENSAT stage, n | |||
| Stage I–II | 8 | 13 | <0.05 |
| Stage III–IV | 17 | 8 |
| Clinicopathological Features . | Functional ACC (n = 25) . | Nonfunctional ACC (n = 21) . | P . |
|---|---|---|---|
| Age at diagnosis, ya | 57.0 (44.0, 63.0) | 54.0 (42.5, 58.5) | 0.76 |
| Sex, male/female | 13/12 | 8/13 | 0.35 |
| Primary tumor size, cma | 9.23 (5.89, 10.95) | 7.90 (5.80, 10.21) | 0.70 |
| ENSAT stage, n | |||
| Stage I–II | 8 | 13 | <0.05 |
| Stage III–IV | 17 | 8 |
P < 0.05 was considered statistically significant.
Data are expressed as medians and interquartile ranges.
| Clinicopathological Features . | Functional ACC (n = 25) . | Nonfunctional ACC (n = 21) . | P . |
|---|---|---|---|
| Age at diagnosis, ya | 57.0 (44.0, 63.0) | 54.0 (42.5, 58.5) | 0.76 |
| Sex, male/female | 13/12 | 8/13 | 0.35 |
| Primary tumor size, cma | 9.23 (5.89, 10.95) | 7.90 (5.80, 10.21) | 0.70 |
| ENSAT stage, n | |||
| Stage I–II | 8 | 13 | <0.05 |
| Stage III–IV | 17 | 8 |
| Clinicopathological Features . | Functional ACC (n = 25) . | Nonfunctional ACC (n = 21) . | P . |
|---|---|---|---|
| Age at diagnosis, ya | 57.0 (44.0, 63.0) | 54.0 (42.5, 58.5) | 0.76 |
| Sex, male/female | 13/12 | 8/13 | 0.35 |
| Primary tumor size, cma | 9.23 (5.89, 10.95) | 7.90 (5.80, 10.21) | 0.70 |
| ENSAT stage, n | |||
| Stage I–II | 8 | 13 | <0.05 |
| Stage III–IV | 17 | 8 |
P < 0.05 was considered statistically significant.
Data are expressed as medians and interquartile ranges.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
